Advances in the Management of Intrahepatic Cholangiocarcinoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 July 2024 | Viewed by 87
Special Issue Editor
Interests: CRLM; HCC; perihilar cholangiocarcinoma; intrahepatic cholangiocarcinoma; molecular profiling
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver tumor, with a rising incidence in Western countries. Surgery is the current standard of care, but liver resection for iCCA is usually very demanding. Extended liver resections, often in combination with complex vascular and biliary reconstructions, are usually needed to achieve an R0 situation. However, only a few patients are candidates for upfront surgery. Most frequently, iCCA is diagnosed in an advanced tumor stage when prognosis is dismal. In recent years, significant progress in the management of iCCA has been made. Adjuvant treatment has become standard, and encouragingly, first results obtained after neoadjuvant treatment show the possibility of successful downsizing as well as improvements in resection and survival rates. Further, iCCA has become a hallmark of modern precision medicine, and recent studies even suggest the effectiveness of checkpoint inhibitors. Thus, the treatment of iCCA, more than ever, requires an interdisciplinary approach and open dialogue.
The present Special Issue aims to provide a comprehensive overview of the pathologic and epidemiologic background of iCCA as well as treatment options ranging from systemic or locoregional palliative treatment to potential curative surgical approaches. Finally, future directions in the interdisciplinary management of iCCA with a special focus on molecular profiling and the potential use of neoadjuvant therapy will be delineated.
Prof. Dr. Hauke Lang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- intrahepatic cholangiocarcinoma
- molecular profiling of intrahepatic cholangiocarcinoma
- systemic therapy
- targeted therapy
- immuno-therapy
- neoadjuvant treatment and downsizing
- liver resection
- liver transplantation
- interventional treatment and SIRT
